Milrinone is used during cardiac surgery to facilitate separation from cardiopulmonary bypass (CPB) and/or to treat myocardial dysfunction in the post-bypass period. We have demonstrated, in patients with preoperative depression of systolic function undergoing aorto-coronary artery bypass surgery, sustained improvement in cardiac function after a single loading dose of milrinone 50 g kg
Milrinone is an inodilator commonly used to improve myocardial function. Its main mechanism of action is via inhibition of fraction III of the enzyme phosphodiesterase, thus increasing intracellular concentrations of cyclic AMP in the myocardium. The current recommended dose is a bolus of 50 g kg 91 , followed by continuous infusion of 0.5 g kg 91 min 91 to maintain therapeutic serum concentrations. 1 The purpose of this study was to test the hypothesis that in patients undergoing coronary artery bypass graft (CABG) surgery with pre-existing mild to moderate systolic dysfunction, prophylactic administration of a single dose of milrinone produces sustained improvement in cardiac function, thus decreasing the need for continuous infusion of milrinone and/or a beta agonist.
Methods and results
After obtaining approval from the local Institutional Review Board, we studied 21 consenting adult patients undergoing coronary revascularization, allocated randomly to receive a single dose of milrinone 50 g kg 91 or placebo (normal saline solution) before separation from CPB. All patients had mild to moderate preoperative left ventricular dysfunction (LVEF) (30-50%).
The anaesthetic technique comprised a total dose of fentanyl 50 g kg 91 and midazolam 0.15 mg kg
91
, supplemented with pancuronium and isoflurane. Radial arterial and pulmonary artery catheters (Abbott Laboratories, Mountainview, CA, USA) were inserted after induction of anaesthesia, as is usual in our institution. All pressures were measured with transducers referenced at the level of the right atrium. Cardiac index was determined via thermodilution. A transoesophageal multiplane ultrasound transducer (Omniplane Hewlett-Packard, SONOS 1500, Andover, MA, USA) was placed at the level of the left ventricular short axis at the mid-papillary muscle level. End-diastolic (EDA) and end-systolic (ESA) area were measured, and fractional area of change (FAC) evaluated using automatic border detection. Haemodynamic-derived indices were calculated according to standard formulae.
All patients were operated on by the same surgeon using the same technique. The distal coronary anastomoses were constructed under CPB with moderate hypothermia (bladder temperature 28ЊC) after application of the aortic cross-clamp. Tepid blood cardioplegia (dilution: 1 part blood, 3 parts crystalloid) was infused via the aortic root and coronary sinus with repeated doses given via the aortic root every 20-30 min. The proximal anastomses were constructed with a partial occlusion clamp during rewarming, with the heart beating spontaneously or electrically paced.
Towards the end of CPB, patients received a loading dose of milrinone 50 g kg 91 (n:11) or normal saline solution (n:10) over 10 min into the bypass pump. Haemodynamic measurements and FAC were determined within 5 min after termination of CPB, 30 min later and at the end of surgery. Dobutamine, at a starting dose of 5 g kg for dobutamine and phenylephrine were analysed by chi-square test. There were no significant differences between groups for incidence of congestive heart failure, medication or LVEF before operation. Intraoperative mean CPB time, aortic cross-clamp time, number of grafts, packed cell volume and ionized calcium were also similar. All patients achieved successful separation from CPB during the initial attempt. Dobutamine (mean dose 7 g kg 91 min
) was required in eight patients in the placebo group compared with none in the milrinone group immediately after termination of CPB (P:0.05). At 30 min after CPB, three patients in the milrinone group required dobutamine (mean dose 5 g kg 91 min
). No further inotropic adjustment was necessary in any of these patients at the end of surgery. Haemodynamic data from both groups after CPB are shown in table 1. There was no difference in heart rate between groups; cardiac index and FAC were significantly higher, and SVRI was consistently lower in the milrinone group at all times. With milrinone, 5 of 11 patients required phenylephrine to maintain mean arterial pressure 960 mm Hg compared with two of 10 patients in the placebo-dobutamine group (P:0.05). Time from termination of CPB to the end of surgery averaged 70 min in the milrinone group and 72 min in the placebo group.
Comment
Milrinone has been used for the treatment of low output syndrome caused by myocardial dysfunction after CPB. It is more potent than amrinone, and its use is not associated with thrombocytopenia. Pharmacokinetic data have shown that, unlike amrinone, when milrinone is administered before termination of bypass, no modifications in the loading dose for the added volume of the CPB circuit are necessary. 1 Milrinone 50 g kg
91
, given 10-20 min before the end of extracorporeal circulation, produces concentrations greater than 100 ng dl 91 which are associated with an increased cardiac index.
1 However, after a loading dose, serum concentrations decline within 30 min; thus, in the presence of normal renal function, continuous infusion of 0.5 g kg 91 min 91 is recommended to maintain serum concentrations greater than 100 ng dl 91 . 1 Our results confirm the experience of Butterworth and colleagues who demonstrated improved haemodynamic state and lesser need for inotropes in patients receiving amrinone compared with placebo at the end of CPB. 2 We observed that administration of a single prophylactic loading dose of milrinone was associated with significant improvement in haemodynamic state in addition to echocardiographic indices of systolic function, comparing favorably with those receiving dobutamine in the placebo group. Haemodynamic improvement was still present 70 min after bypass. Phenylephrine was required more often in milrinone-treated patients (but without adverse effect). In our experience and that of others, phenylephrine is commonly used to treat excessive vasodilatation and is not associated with adverse effects.
Milrinone improves cardiac function by increasing contractility and decreasing afterload. 3 It also improves coronary blood flow and may improve recovery after myocardial stunning. 4 It is possible that while serum concentrations seem to correlate with the inotropic effects of the drug, effects on the systemic vasculature and myocardial blood flow after reperfusion may contribute to the more pronounced and sustained improvement seen in this group of patients, even after serum concentrations based on previous pharmacokinetic data might have declined to subtherapeutic levels. Separate analysis of the inotropic from the vasodilatory effects of inodilators is possible via determination of end-systolic and arterial elastance using pressure-volume loops; 5 however, this was not the objective of the study. Also, as suggested with amrinone, administration of milrinone may offer some protection from post-bypass ischaemia, which would result in long term improved performance. 6 In summary, we have shown that in patients with mild depression of systolic function before operation, administration of a loading dose of milrinone 50 g kg 91 was associated with sustained haemodynamic improvement, in addition to increases in cardiac function that persisted until the end of surgery. 
